

1. **Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR, and Dawson DW.** The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. *Molecular cancer therapeutics* 13: 2303-2314, 2014.
2. **Arias-Romero LE, Villamar-Cruz O, Huang M, Hoeflich KP, and Chernoff J.** Pak1 kinase links ErbB2 to beta-catenin in transformation of breast epithelial cells. *Cancer research* 73: 3671-3682, 2013.
3. **Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, and van Stolk RU.** A randomized trial of aspirin to prevent colorectal adenomas. *The New England journal of medicine* 348: 891-899, 2003.
4. **Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, and Lum L.** Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. *Nature chemical biology* 5: 100-107, 2009.
5. **Chen HJ, Hsu LS, Shia YT, Lin MW, and Lin CM.** The beta-catenin/TCF complex as a novel target of resveratrol in the Wnt/beta-catenin signaling pathway. *Biochemical pharmacology* 84: 1143-1153, 2012.
6. **Chen X, and Deng Y.** Simulations of a specific inhibitor of the dishevelled PDZ domain. *Journal of molecular modeling* 15: 91-96, 2009.
7. **Chen Z, Venkatesan AM, Dehnhardt CM, Dos Santos O, Delos Santos E, Ayril-Kaloustian S, Chen L, Geng Y, Arndt KT, Lucas J, Chaudhary I, and Mansour TS.** 2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer. *Bioorganic & medicinal chemistry letters* 19: 4980-4983, 2009.
8. **DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, and Rubinfeld B.** The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. *Cancer research* 67: 5371-5379, 2007.
9. **Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR, and Kahn M.** A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. *Proceedings of the National Academy of Sciences of the United States of America* 101: 12682-12687, 2004.
10. **Fu Y, Chang H, Peng X, Bai Q, Yi L, Zhou Y, Zhu J, and Mi M.** Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/beta-catenin signaling pathway. *PloS one* 9: e102535, 2014.
11. **Fuchs CS, and Ogino S.** Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex! *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 31: 4358-4361, 2013.
12. **Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK, and Jablons DM.** An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. *Cancer research* 67: 573-579, 2007.
13. **Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AM, and DasGupta R.** An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. *Proceedings of the National Academy of Sciences of the United States of America* 108: 5954-5963, 2011.
14. **Grandy D, Shan J, Zhang X, Rao S, Akunuru S, Li H, Zhang Y, Alpatov I, Zhang XA, Lang RA, Shi DL, and Zheng JJ.** Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. *The Journal of biological chemistry* 284: 16256-16263, 2009.
15. **Grosch S, Tegeder I, Niederberger E, Brautigam L, and Geisslinger G.** COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 15: 2742-2744, 2001.

16. **Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J, and Hoey T.** Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. *Proceedings of the National Academy of Sciences of the United States of America* 109: 11717-11722, 2012.
17. **He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, and Jablons DM.** A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. *Neoplasia* 6: 7-14, 2004.
18. **He M, Li Y, Zhang L, Li L, Shen Y, Lin L, Zheng W, Chen L, Bian X, Ng HK, and Tang L.** Curcumin suppresses cell proliferation through inhibition of the Wnt/beta-catenin signaling pathway in medulloblastoma. *Oncology reports* 32: 173-180, 2014.
19. **Hu J, Dong A, Fernandez-Ruiz V, Shan J, Kawa M, Martinez-Anso E, Prieto J, and Qian C.** Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. *Cancer research* 69: 6951-6959, 2009.
20. **Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, and Cong F.** Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. *Nature* 461: 614-620, 2009.
21. **Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, Wazer DE, Paulson KE, and Yee AS.** Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. *The Journal of biological chemistry* 281: 10865-10875, 2006.
22. **Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, and Shivdasani RA.** Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. *Cancer cell* 5: 91-102, 2004.
23. **Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarreal MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, and Harris JL.** Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. *Proceedings of the National Academy of Sciences of the United States of America* 110: 20224-20229, 2013.
24. **Maier TJ, Janssen A, Schmidt R, Geisslinger G, and Grosch S.** Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 19: 1353-1355, 2005.
25. **Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, and Munoz A.** Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. *The Journal of cell biology* 154: 369-387, 2001.
26. **Park CH, Chang JY, Hahm ER, Park S, Kim HK, and Yang CH.** Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. *Biochemical and biophysical research communications* 328: 227-234, 2005.
27. **Rhee CS, Sen M, Lu D, Wu C, Leoni L, Rubin J, Corr M, and Carson DA.** Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. *Oncogene* 21: 6598-6605, 2002.
28. **Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, and Sasaguri T.** Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. *Biochemical pharmacology* 73: 1318-1329, 2007.
29. **Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, and Schilsky R.** A randomized trial of aspirin to prevent colorectal

adenomas in patients with previous colorectal cancer. *The New England journal of medicine* 348: 883-890, 2003.

30. **Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, and Weinstein IB.** (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. *Clinical cancer research : an official journal of the American Association for Cancer Research* 11: 2735-2746, 2005.

31. **Soprano DR, Qin P, and Soprano KJ.** Retinoic acid receptors and cancers. *Annual review of nutrition* 24: 201-221, 2004.

32. **Thun MJ, Namboodiri MM, and Heath CW, Jr.** Aspirin use and reduced risk of fatal colon cancer. *The New England journal of medicine* 325: 1593-1596, 1991.

33. **Tian W, Han X, Yan M, Xu Y, Duggineni S, Lin N, Luo G, Li YM, Han X, Huang Z, and An J.** Structure-based discovery of a novel inhibitor targeting the beta-catenin/Tcf4 interaction. *Biochemistry* 51: 724-731, 2012.

34. **Trosset JY, Dalvit C, Knapp S, Fasolini M, Veronesi M, Mantegani S, Gianellini LM, Catana C, Sundstrom M, Stouten PF, and Moll JK.** Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. *Proteins* 64: 60-67, 2006.

35. **Waler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D, Voronkov A, von Kries JP, and Krauss S.** A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. *Cancer research* 72: 2822-2832, 2012.

36. **Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, Gary BD, Keeton AB, Xi Y, Abadi AH, Grizzle WE, and Piazza GA.** A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and beta-catenin transcriptional activity. *Cancer prevention research* 5: 822-833, 2012.

37. **You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A, McCormick F, and Jablons DM.** Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. *Cancer research* 64: 3474-3478, 2004.

38. **You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F, and Jablons DM.** An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. *Cancer research* 64: 5385-5389, 2004.

39. **You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, and Jablons DM.** Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. *Oncogene* 23: 6170-6174, 2004.